European facilities now handle 50% of new drug dose manufacturing contracts, up from 25–35% in 2023, while US share stagnates at 18%.
European contract manufacturing facilities secured 50% of dose outsourcing contracts for newly approved drugs in 2025, nearly doubling their share since 2023. US-based facilities held steady at 18%, widening the gap between the two regions.
The shift follows years of fluctuation, with Europe consistently leading since 2023. US facilities briefly neared parity in 2018, 2021, and 2023 but failed to sustain momentum. Tax policies and specialized capabilities are cited as key drivers.
Data for the first half of 2026 suggests the trend is accelerating, with no signs of US facilities closing the gap.